SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the presentation of pre-clinical data demonstrating that SCV-07 in an oral formulation retains its immunomodulatory properties and is as effective as the standard injection formulation against tuberculosis (TB) in an animal model study. Alexander Kolobov, Ph.D. of Verta, Ltd. presented these data yesterday at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS) held in San Francisco, CA.
